ReviewCurrent topics in microbiology and immunology2025
Antifungal Drug Resistance.
Review in Current topics in microbiology and immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Antimicrobial Potential of Defensin-DerivedInternational journal of molecular sciences · 2026Article
- Yeast infections in sterile body fluids: species distribution, antifungal susceptibility, and cross-cutting risk factors for fungemia, sepsis, and mortality (2019-2023).Frontiers in microbiology · 2026Article
- Genes and physiological strategies in bacterial antibiotic resistance.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal infections pose an important threat to public health and food security, and with the rise in antifungal drug and fungicide resistance, we are faced with a global crisis. Currently, humanity is at an intersection of global climate change driving the expansion of species range distributions, emergence of novel pathogenic fungi, and changing at-risk populations. Here, we review the main mechanisms of antifungal drug and fungicide resistance, new drugs and mode-of-action drug classes, and future topics for risk reduction. We propose that integrating One Health and surveillance is a crucial first step in addressing this issue. Additionally, we emphasise that global collaboration among multiple stakeholders is essential to reverse the current upward trend in observed resistance. Finally, plant and medical mycologists can and should work together for the creation of a common language and antifungal stewardship plan.
Indexed as
Identifiers
40908337What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.